Treatment of Complicated Staphylococcus aureus Bacteremia
Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ. Related Content: Dalbavancin for Treatment of Staphylococcus aureus Bacteremia Management of Staphylococcus aureus Bacteremia ----------------------------------- JAMA Editors' Summary
--------
11:35
--------
11:35
Diagnosis and Management of Prostatitis
Prostatitis affects approximately 9.3% of men in their lifetime and includes acute and chronic bacterial infection and nonbacterial chronic prostatitis with chronic pelvic pain syndrome. Author Minh N. Pham, MD, from University of North Carolina School of Medicine discusses this and more with JAMA Deputy Editor Mary M. McDermott, MD. Related Content: Prostatitis ----------------------------------- JAMA Editors' Summary
--------
17:51
--------
17:51
Geroscience in Medicine
Geroscience aims to define and modify biologic pathways associated with aging and age-related diseases. Author Stephen B. Kritchevsky, PhD, of the Wake Forest University School of Medicine and JAMA Deputy Editor Mary M. McDermott, MD, discuss current evidence regarding geroscience, human health, and promising therapies that may slow aging and age-related decline. Related Content: Geroscience ----------------------------------- JAMA Editors' Summary
--------
16:23
--------
16:23
Managing Adverse Effects of Obesity Medications
New medications for obesity, such as semaglutide and tirzepatide, are highly effective but can be associated with adverse effects that reduce adherence. Obesity expert and author Robert Kushner, MD, joins JAMA Deputy Editor Mary McDermott, MD, to discuss a recent JAMA Insights article on managing adverse effects of obesity medications. Related Content: Managing Adverse Effects of Incretin-Based Medications for Obesity ----------------------------------- JAMA Editors' Summary
--------
12:21
--------
12:21
Patent Foramen Ovale-Associated Stroke
A patent foramen ovale (PFO) is present in approximately 25% of all adults. Author David M. Kent, MD, MS, of Tufts Medical Center and JAMA Associate Editor David Simel, MD, MHS, discuss how to evaluate the likelihood that a PFO was causal in a patient with a cryptogenic ischemic stroke, and closure of a PFO to lower the incidence of recurrent strokes for affected patients. Related Content: Patent Foramen Ovale and Stroke Patent Foramen Ovale and Dysarthria in a Man in His 60s Management of Patients With a Patent Foramen Ovale With History of Stroke or TIA Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke Transesophageal Echocardiogram Detecting a High-Risk Patent Foramen Ovale ----------------------------------- JAMA Editors' Summary
USA